This review sought to evaluate the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy on the weight of patients with type 2 diabetes mellitus and compare them with other glucose-lowering medications. The researchers included studies (n=29) administering SGLT2 for at least 12 weeks; the resulting sample yielded data from 11,999 patients. The results indicated greater weight loss with canagliflozin and with ipragliflozin compared to metformin. Canagliflozin was associated with a greater extent of weight loss compared to other SGLT2 inhibitors in the analysis. “The weight reduction effect of 300 mg canagliflozin is greater than that of most other SGLT2 inhibitors. More types of SGLT2 inhibitors in a head-to-head trial, as well as a comparison between SGLT2 inhibitors and glucagon-like peptide 1 receptor agonists, will be involved in our further research,” the researchers added in their conclusion.
Source: Wang H, Yang J, Chen X, Qiu F, Li J. Clin Ther. 2019;doi:10.1016/j.clinthera.2019.01.001